BioMed Research International / 2019 / Article / Tab 1

Clinical Study

Elevated Preoperative Serum CA125 Predicts Larger Tumor Diameter in Patients with Hepatocellular Carcinoma and Low AFP Levels

Table 1

Baseline characteristics of the entire patients (n = 427).

CharacteristicsNo. of patientsProportion (%)

Age (years), mean ± SD56.7 ± 9.5
Gender
 Male36685.7
 Female6114.3
Cirrhosis
 Yes36685.7
 No6114.3
Virus hepatitis
 HBV35984.1
 HCV81.9
 Non-HBC, non-HCV6014.0
Antiviral treatment
 Yes35984.1
 No6815.9
Child-Pugh
 A41597.2
 B122.8
ALT (U/L), median (IQR)36.0 (25.0–51.0)
T-Bil (umol/L), median (IQR)14.8 (11.2–19.4)
Anatomical resection
 Yes14634.2
 No28165.8
Surgical margin (mm)
 ≤1036485.2
 >106314.8
MTD (cm)
 ≤532074.9
 >510725.1
Number of nodules
 136385.0
 >16415.0
Microvascular invasion
 Yes9121.1
 No33678.7
Differentiation
 Well5011.7
 Mod, poor37788.3
TNM stage
 I32876.8
 II6014.1
 III399.1

HBV, viral hepatitis B; HCV, viral hepatitis C; ALT, alanine transaminase; T-Bil, total bilirubin; MTD, maximal tumor diameter; IQR, interquartile range. In this study, out of a total of 427 patients, 359 were HBV-related HCC patients. They were all treated with nucleic acid analog for hepatitis B. TNM stages were assigned according to the criteria described in the AJCC Cancer Staging Manual (8th Edition).

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.